Oncology

Latest News

The report suggests a TBS cutoff value of 3 will serve as a meaningful prognostic tool in HCC, but differences in patient populations and imaging techniques may affect the value of that cutoff, the authors noted. | Image credit: Jo Panuwat D - stock.adobe.com
HCC Tumor Burden Score Predicts Long-Term Outcomes Following MWA

May 7th 2025

Patients with a high tumor burden score had poorer outcomes following microwave ablation, the investigators found.

Doctor showing lung x ray | Image credit: didesign – stock.adobe.com
Tarlatamab Safety Varies Between Clinical and Real-World SCLC Trials

May 6th 2025

CureCancer | Image Credit: © MMPhoto21-sotck.adobe.com
COA 2025: Insight, Innovation, and Independent Strength

May 5th 2025

COA logo | Image Credit: © Amy Kinnamon
Community Oncology Reacts to Trump's Drug Pricing Executive Order

May 2nd 2025

Melanoma & Skin Cancer Awareness Month | Image credit: Waseem Ali Khan - stock.adobe.com
5 Things You Should Know About Skin Cancer

May 2nd 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

Site Logo
June 18th 2019

Two-Sided Risk in the Oncology Care Model

Kashyap Patel, MD, ABOIM, BCMAS Maharshi Patel, MBA Taylor Lavender, BS, PA Dhwani Mehta, MS RD Asutosh Gor, MD, Sashi Naidu, MD Chuck Newton, BS
The US healthcare system remains one of the most inefficient healthcare systems in the world. The Bloomberg Health-Care Efficiency Index ranked the United States 54th among 56 countries in 2018, tied with Azerbaijan and only ahead of Bulgaria. This occurs even though the United States spends $10,244 per capita annually on healthcare, a figure representing 17% of the gross domestic product.
Site Logo
June 18th 2019

MIT Group Brings Together Stakeholders to Brainstorm How to Pay for Curative Therapies Over Time

Mary Caffrey
More and more, stakeholders across the healthcare system— providers, commercial payers, pharmaceutical companies, large employers, state Medicaid officials, and even state budget officers—are grappling with the fact that the old pay-as-you-go way of covering medicines, even cancer drugs, was not built for these revolutionary therapies. A group at MIT is developing new models, which use reinsurance and payments over time to fund these durable treatments.
Site Logo
June 17th 2019

US Care Pathways: Continued Focus on Oncology and Outstanding Challenges

Anita Chawla, PhD Kimberly Westrich, MA Angela Dai, BS, BA Sarah Mantels, MA Robert W. Dubois, MD, PhD
The authors examined the latest trends in development, implementation, and evaluation of care pathways and the impact of the movement toward value-based care.
Dr Bruce Feinberg Highlights Use of Chemotherapy in Breast Cancer
June 16th 2019

Dr Bruce Feinberg Highlights Use of Chemotherapy in Breast Cancer

Is chemotherapy really on its way out? Maybe not, said Bruce Feinberg, DO, vice president and chief medical officer of Cardinal Health Specialty Solutions.
Podcast: This Week in Managed Care—USPSTF Recommends PrEP for HIV and Other Health News
June 16th 2019

Podcast: This Week in Managed Care—USPSTF Recommends PrEP for HIV and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.
Site Logo
June 14th 2019

Cancer Care Spending and Use by Site of Provider-Administered Chemotherapy in Medicare

Andrew Shooshtari, BS Yamini Kalidindi, MHA Jeah Jung, PhD
Differences in cancer care spending and utilization between Medicare beneficiaries receiving chemotherapy in hospital outpatient departments versus physician offices vary by service type.
Exploring Oncology Financial Toxicity, Cost of Care
June 14th 2019

Exploring Oncology Financial Toxicity, Cost of Care

AJMC Staff
Two posters presented at the 2019 American Society of Clinical Oncology Annual Meeting, held May 31 to June 4, 2019, in Chicago, Illinois, discussed the growing issue of financial toxicity and the costs of care in cancer treatment.
Site Logo
June 14th 2019

Understanding Price Growth in the Market for Targeted Oncology Therapies

Jesse Sussell, PhD Jacqueline Vanderpuye-Orgle, PhD Diana Vania, MSc Hans-Peter Goertz, MPH Darius Lakdawalla, PhD
The prices of targeted oncology therapies have grown substantially, but revenues have not. This is due in part to large declines in per-drug patient counts.
Does Chemotherapy Still Have a Role to Play in Cancer Care?
June 13th 2019

Does Chemotherapy Still Have a Role to Play in Cancer Care?

As new innovations in cancer care reach the market, some people seem ready to move on from chemotherapy, but the treatment will still have a role to play in treating cancer for years, if not decades, to come.
Site Logo
June 13th 2019

Reports of the Demise of Chemotherapy Have Been Greatly Exaggerated

Bruce Feinberg, DO Jonathan Kish, PhD, MPH Igoni Dokubo, MD Jeff Wojtynek, PharmD Kevin Lord, PhD, MHS
The expanding arsenal of targeted and immuno-oncology drugs has unalterably changed the landscape of systemic cancer treatment, but chemotherapy will remain critical for years if not decades to come.
Entrectinib Demonstrates Efficacy in Rare Lung Cancer, Pediatric Solid Tumors
June 11th 2019

Entrectinib Demonstrates Efficacy in Rare Lung Cancer, Pediatric Solid Tumors

Jaime Rosenberg
A pair of study abstracts presented at the 2019 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois, supported the efficacy of entrectinib among 2 different groups of patients, including patients with a rare form of lung cancer and pediatric and adolescent patients with solid tumors.
David Ortiz Explains How OCM Is Changing Cancer Care Delivery
June 9th 2019

David Ortiz Explains How OCM Is Changing Cancer Care Delivery

The Oncology Care Model (OCM) is pushing cancer centers and cancer programs to make the changes they knew were needed to improve care delivery and patient experiences, said David Ortiz, OCM program director at Montefiore Einstein Center for Cancer Care.
Dr Bruce Feinberg Discusses Speculation of the End of Chemotherapy in Cancer
June 6th 2019

Dr Bruce Feinberg Discusses Speculation of the End of Chemotherapy in Cancer

There has been much speculation about the end of chemotherapy in cancer treatment, but it’s not clear how accurate that is, said Bruce Feinberg, DO, vice president and chief medical officer of Cardinal Health Specialty Solutions.
Outlining the Risks That Go Along With the Benefit of CAR T-Cell Therapy
June 5th 2019

Outlining the Risks That Go Along With the Benefit of CAR T-Cell Therapy

Samantha DiGrande
Though chimeric antigen receptor (CAR) T-cell therapy has been largely touted as one of the most important advances in cancer care in recent years, the therapy comes with the risk of severe toxicities as well as increased financial burden due to the high cost of the drugs.
COA Urges Delay in Downside Risk Deadline for OCM
June 5th 2019

COA Urges Delay in Downside Risk Deadline for OCM

Jaime Rosenberg
Outlining a set of issues that need to be addressed under the Oncology Care Model (OCM), the Community Oncology Alliance (COA) is urging the Center for Medicare & Medicaid Innovation to delay the October 2019 deadline for practices to transition to 2-sided risk under the model.
The Importance of Including Primary Care Physicians in a Patient's Cancer Journey
June 1st 2019

The Importance of Including Primary Care Physicians in a Patient's Cancer Journey

Samantha DiGrande
“How do you currently collaborate with your primary care colleagues in caring for patients with cancer?” This was how Larissa Nekhlyudov, MD, MPH, opened a session titled “Bringing the Primary Care Physician Back Into Cancer Care,” during the American Society of Clinical Oncology’s Annual Meeting, held in Chicago, Illinois from May 31-June 4, 2019.
Unlocking the Promise of Vaccines for Cancer Treatment
May 31st 2019

Unlocking the Promise of Vaccines for Cancer Treatment

Jaime Rosenberg
This is part 3 of a 3-part vaccine series covering the potential of vaccines for infectious diseases, the impact of the antivaccination movement, and the promise of vaccines for cancer treatment. Read part 1 and part 2.
KOL Corner: Amy Ellis Discusses Practice Transformation With Jess Quiring of New Mexico Cancer Center
May 30th 2019

KOL Corner: Amy Ellis Discusses Practice Transformation With Jess Quiring of New Mexico Cancer Center

In the first of a series of interviews with key opinion leaders (KOLs), Amy Ellis, director of quality and value-based care at Northwest Medical Specialties, discusses practice transformation with Jess Quiring, a patient navigator at New Mexico Cancer Center.
Pediatric Patients Wait an Average of 6.5 Years Longer Than Adults to Access New Oncology Drugs
May 29th 2019

Pediatric Patients Wait an Average of 6.5 Years Longer Than Adults to Access New Oncology Drugs

Jaime Rosenberg
The median lag time from first-in-human to first-in-child trials of oncology drugs that were ultimately approved by FDA is 6.5 years.
David Ortiz Discusses Making Adjustments, Reacting to Performance Period Reports in OCM
May 28th 2019

David Ortiz Discusses Making Adjustments, Reacting to Performance Period Reports in OCM

The long time between when a performance period ends and when the report comes out in the Oncology Care Model (OCM) can make it difficult to measure the impact specific changes are making, said David Ortiz, OCM program director at Montefiore Einstein Center for Cancer Care.
Immunotherapy and the OCM: Costs and Utilization
May 21st 2019

Immunotherapy and the OCM: Costs and Utilization

Oncology Care Model: Stakeholder Support
May 21st 2019

Oncology Care Model: Stakeholder Support

Improving Upon the Oncology Care Model Framework
May 21st 2019

Improving Upon the Oncology Care Model Framework

Oncology Care Model: Measuring Value
May 21st 2019

Oncology Care Model: Measuring Value

Evolving Versions of the Oncology Care Model
May 21st 2019

Evolving Versions of the Oncology Care Model

Novel Therapies & The OCM: Treatment Decisions
May 21st 2019

Novel Therapies & The OCM: Treatment Decisions

Oncology Care Model: Counseling Patients
May 21st 2019

Oncology Care Model: Counseling Patients

Opportunities of the Oncology Care Model
May 21st 2019

Opportunities of the Oncology Care Model

Oncology Care Model: Measuring Performance
May 21st 2019

Oncology Care Model: Measuring Performance

Practice Pathways Under the Oncology Care Model
May 21st 2019

Practice Pathways Under the Oncology Care Model

<1
...
242526272829303132
...
184>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo